Coherus BioSciences Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $516.67 million
- Book Value:
- Revenue TTM:
- $211.04 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Coherus BioSciences Inc had its IPO on 2014-11-06 under the ticker symbol CHRS.
The company operates in the Healthcare sector and Biotechnology industry. Coherus BioSciences Inc has a staff strength of 359 employees.
Shares of Coherus BioSciences Inc opened at $6.5 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $6.36 - $6.55, and closed at $6.43.
This is a -0.77% slip from the previous day's closing price.
A total volume of 1,075,204 shares were traded at the close of the day’s session.
In the last one week, shares of Coherus BioSciences Inc have increased by +9.17%.
Coherus BioSciences Inc's Key Ratios
Coherus BioSciences Inc has a market cap of $516.67 million, indicating a price to book ratio of 73.1897 and a price to sales ratio of 2.3539.
In the last 12-months Coherus BioSciences Inc’s revenue was $211.04 million with a gross profit of $-58399000 and an EBITDA of $-253180992. The EBITDA ratio measures Coherus BioSciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Coherus BioSciences Inc’s operating margin was -121.72% while its return on assets stood at -27.68% with a return of equity of -1657.06%.
In Q4, Coherus BioSciences Inc’s quarterly earnings growth was a negative -75.5% while revenue growth was a negative 38.2%.
Coherus BioSciences Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-4.02 per share while it has a forward price to earnings multiple of 32.8947 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Coherus BioSciences Inc’s profitability.
Coherus BioSciences Inc stock is trading at a EV to sales ratio of 3.2024 and a EV to EBITDA ratio of -3.1091. Its price to sales ratio in the trailing 12-months stood at 2.3539.
Coherus BioSciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $480.85 million
- Total Liabilities
- $138.69 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Coherus BioSciences Inc ended 2023 with $480.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $480.85 million while shareholder equity stood at $-137418000.00.
Coherus BioSciences Inc ended 2023 with $0 in deferred long-term liabilities, $138.69 million in other current liabilities, 8000.00 in common stock, $-1341608000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $63.55 million and cash and short-term investments were $191.68 million. The company’s total short-term debt was $4,318,000 while long-term debt stood at $225.58 million.
Coherus BioSciences Inc’s total current assets stands at $381.23 million while long-term investments were $0 and short-term investments were $128.13 million. Its net receivables were $109.96 million compared to accounts payable of $11.53 million and inventory worth $38.79 million.
In 2023, Coherus BioSciences Inc's operating cash flow was $-129898000.00 while its capital expenditure stood at $87000.
Comparatively, Coherus BioSciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Coherus BioSciences Inc stock is currently trading at $6.43 per share. It touched a 52-week high of $14.11 and a 52-week low of $14.11. Analysts tracking the stock have a 12-month average target price of $17.13.
Its 50-day moving average was $7.35 and 200-day moving average was $8.44 The short ratio stood at 9.83 indicating a short percent outstanding of 0%.
Around 214.2% of the company’s stock are held by insiders while 10500.6% are held by institutions.
Frequently Asked Questions About Coherus BioSciences Inc
Similar Industry Stocks (Biotechnology)
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.